BAY43-9006
Showing 1 - 25 of 1,296
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer Trial in
Completed
- Acinar Cell Adenocarcinoma of the Pancreas
- +4 more
- sorafenib tosylate
- +4 more
-
Aurora, Colorado
- +1 more
Sep 8, 2022
Called ROCURS, to Learn About COVID-19 Related Outcomes in
Active, not recruiting
- Malignant Solid Tumors
- +2 more
- Non-TKIs
- +3 more
-
Whippany, New JerseyBayer
Feb 2, 2023
Prospective, Non-interventional, Post-authorization Safety Study
Active, not recruiting
- Thyroid Carcinoma
- Sorafenib (Nexavar, BAY43-9006)
-
Multiple Locations, Japan(unnamed)
Aug 18, 2022
The Gut Microbiome in FLT3- AL Undergoing Allo-HSCT With Or
Recruiting
- Acute Leukemia
- Allogeneic Hematopoietic Stem Cell Transplantation
-
Guangzhou, Guangdong, ChinaDepartment of Hematology,Nanfang Hospital, Southern Medical Univ
Oct 28, 2022
Melanoma (Skin) Trial in Philadelphia (sorafenib tosylate, temozolomide)
Completed
- Melanoma (Skin)
- sorafenib tosylate
- temozolomide
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jun 13, 2022
The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD
Recruiting
- Acute Myeloid Leukemia With FLT3/ITD Mutation
- Allogeneic Hematopoietic Stem Cell Transplantation
-
Guangzhou, Guangdong, ChinaDepartment of Hematology,Nanfang Hospital, Southern Medical Univ
Oct 25, 2022
The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or
Recruiting
- Acute Myeloid Leukemia With FLT3/ITD Mutation
- Allogeneic Hematopoietic Stem Cell Transplantation
-
Guangzhou, Guangdong, ChinaDepartment of Hematology,Nanfang Hospital, Southern Medical Univ
Oct 25, 2022
Advanced Cancer Trial in Houston (Temsirolimus, Bevacizumab, Paclitaxel)
Active, not recruiting
- Advanced Cancer
- Temsirolimus
- +4 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Oct 11, 2022
Refractory Solid Tumor, Hepatocellular Carcinoma, Malignant Solid Tumor Trial in Memphis (Atezolizumab, Sorafenib, Bevacizumab)
Recruiting
- Refractory Solid Tumor
- +4 more
- Atezolizumab
- +3 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Aug 4, 2022
Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Recurrent Adult Hepatocellular Carcinoma Trial
Completed
- Advanced Adult Hepatocellular Carcinoma
- +10 more
- Laboratory Biomarker Analysis
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Dec 1, 2021
Hepatocellular Carcinoma Trial in Hong Kong (Durvalumab, Sorafenib, Lenvatinib)
Recruiting
- Hepatocellular Carcinoma
- Durvalumab
- +4 more
-
Hong Kong, Hong Kong SAR, Hong KongHumanity & Health Research Centre
Mar 16, 2022
Acute Myeloid Leukemia With FLT3/ITD Mutation Trial in Baltimore (Bone Marrow Transplantation, Sorafenib, Sorafenib Tosylate)
Completed
- Acute Myeloid Leukemia With FLT3/ITD Mutation
- Bone Marrow Transplantation
- +2 more
-
Baltimore, Maryland
- +1 more
May 27, 2021
Adult Primary Hepatocellular Carcinoma, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary
Suspended
- Adult Primary Hepatocellular Carcinoma
- +3 more
- sorafenib tosylate
- +2 more
-
Birmingham, Alabama
- +20 more
Aug 29, 2022
Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +3 more
- Decitabine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jun 29, 2022
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage Trial in Houston (Clofarabine,
Recruiting
- Acute Bilineal Leukemia
- +7 more
- Clofarabine
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Co-existing Mutations on Sorafenib Maintenance Therapy After
Completed
- Acute Myeloid Leukemia
- +2 more
-
Guangzhou, Guangdong, ChinaDepartment of Hematology,Nanfang Hospital, Southern Medical Univ
May 30, 2022
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (procedure, drug, biological)
Recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Allogeneic Hematopoietic Stem Cell Transplantation
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7 Trial in Bronx, New York
Completed
- Recurrent Renal Cell Carcinoma
- +2 more
- Capecitabine
- +2 more
-
Bronx, New York
- +3 more
Mar 17, 2021
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Advanced Adult Hepatocellular Carcinoma Trial in
Completed
- Adult Primary Hepatocellular Carcinoma
- +4 more
- Chinese herbal formulation PHY906
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 26, 2021
Pleomorphic Rhabdomyosarcoma, Stage IIB Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7 Trial in
Completed
- Pleomorphic Rhabdomyosarcoma
- +3 more
- Epirubicin Hydrochloride
- +5 more
-
Portland, OregonOHSU Knight Cancer Institute
Feb 23, 2022
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous
Active, not recruiting
- Metastatic Head and Neck Squamous Cell Carcinoma
- +9 more
- Carboplatin
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Apr 27, 2022
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer Trial in
Active, not recruiting
- Adult Primary Hepatocellular Carcinoma
- +2 more
- sorafenib tosylate
- stereotactic body radiation therapy
-
Berkeley, California
- +50 more
Nov 17, 2022
Ovarian Tumor, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial run by the NCI (Bevacizumab, BAY 43-9006)
Completed
- Ovarian Neoplasm
- +2 more
- Bevacizumab
- BAY 43-9006
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Nov 3, 2020
Solid Tumors, Advanced Cancer Trial in Houston (Anastrozole, Bevacizumab, Everolimus)
Completed
- Solid Tumors
- Advanced Cancer
- Anastrozole
- +4 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jan 20, 2021